Resource Library
Reach out to our experts and discover how we can help you advance your research
Contact Us
Resource Library
Reach out to our experts and discover how we can help you advance your research
Contact Us
Resource Library
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
Learn how Cerba Research and Fulgent are enhancing genomic data in clinical trials for better patient outcomes across all phases through their NGS services. In this presentation, you’ll learn how we’re accelerating precision medicine with next generation biomarker discovery through our partnership and specific expertise in oncology, rare disease, CNS, metabolic, and infectious diseases.
Resource Library
Hematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers worldwide, and for approximately 9.5% of newly diagnosed cancers every year.
Due to the high level of heterogeneity in cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.
At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest for novel treatment against hematological malignancies.
Reach out to our experts and discover how we can help you advance your research
Contact Us
Resource Library
Since 1967, Cerba HealthCare Group has accompanied scientific and technological advances in diagnosis, prevention and precision medicine in order to better meet the expectations of health professionals and patients. This constant quest for improvement has led Cerba Research to create one of the world’ s largest and multinational commercial biorepository with the unique goal of contributing to the advancement of Science.
As a specialty and central laboratory for clinical trials covering 5 continents, our biospecimen provision is the starting point for your research to facilitate further downstream decisions inclusion: robust assay development and assay validation with quality samples.
Reach out to our experts and discover how we can help you advance your research
Contact Us
Resource Library
Cerba Research offers in-house in situ biomarkers expertise managed by our research scientists, with over 200 optimized IHC and IF protocols, from simplex to multiplex solutions, to suit the needs of any project. The scientific-driven R&D team can provide complete IHC assay development/optimization or assay transfer of clients’ methods and the subsequent fit-for-purpose validation.
Biomarkers can triple drug development success rates when used in clinical research. While scientific and technological advances have led to the discovery of more circulating biomarker candidates, the challenge lies in validating those biomarkers.
Cerba Research takes a personalized approach to biomarker assay development and validation to help clients improve their odds of success. This approach involves the experience of our leading scientists, and our five-continent laboratory network.
Our highly specialized custom assays, innovative anatomical pathology biomarker support, and biomarker strategies de-risk study conduct and generate the data you need to bring new therapies to light. From translational research to clinical through commercialization, Cerba actuates real-world data to help you reach patients and bring clarity to complex research.
Cerba Research provides flexible, tailored biomarker solutions through a network of labs across five continents. When you partner with us, you gain the operational and scientific expertise to advance targeted approaches and broad immune profiling. Together, we will develop biomarker strategies that help your trial succeed.
But which biomarkers can Cerba Research test on? Discover it here in this downloadable brochure.
Reach out to our experts and discover how we can help advance your research
Contact Us
Resource Library
PBMC-based analytical tests are crucial to accelerating the development of new vaccines, drug discovery, diagnostic development, Precision Medicine Research (e.g., CAR-T cell therapy, gene therapy, etc.), and toxicology applications. To this end, the supply of high-quality PBMC is an essential first step in the process.
Reach out to our experts and discover how we can help you advance your clinical trial
Contact Us
Resource Library
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
In this webinar our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.
Speakers
Submit your information below to watch the webinar or to download the slide deck to receive our expert’s insights.
Reach out to our experts to see how we can help advance your clinical trial
Contact Us
